BD has completed the separation of its Biosciences & Diagnostic Solutions business, which has now combined with Waters Corporation. As part of the transaction, BD shareholders received approximately 0.135 shares of Waters common stock for each BD share held as of February 5, 2026, and BD received $4 billion in cash. Following the deal, BD shareholders own about 39.2% of the combined company. The transaction values the BD Biosciences & Diagnostic Solutions business at $18.8 billion based on Waters’ closing stock price on February 6, 2026. BD plans to use half of the cash proceeds for an accelerated share repurchase program and the remainder for debt repayment. Claire M. Fraser, Ph.D., has joined the Waters Corporation Board of Directors as part of the closing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BD - Becton, Dickinson and Company published the original content used to generate this news brief on February 09, 2026, and is solely responsible for the information contained therein.